98 related articles for article (PubMed ID: 10786665)
1. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.
Zheng FF; Kuduk SD; Chiosis G; Münster PN; Sepp-Lorenzino L; Danishefsky SJ; Rosen N
Cancer Res; 2000 Apr; 60(8):2090-4. PubMed ID: 10786665
[TBL] [Abstract][Full Text] [Related]
2. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
Münster PN; Marchion DC; Basso AD; Rosen N
Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
[TBL] [Abstract][Full Text] [Related]
3. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
4. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
[TBL] [Abstract][Full Text] [Related]
5. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
Ochel HJ; Eichhorn K; Gademann G
Cell Stress Chaperones; 2001 Apr; 6(2):105-12. PubMed ID: 11599571
[No Abstract] [Full Text] [Related]
6. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
Münster PN; Srethapakdi M; Moasser MM; Rosen N
Cancer Res; 2001 Apr; 61(7):2945-52. PubMed ID: 11306472
[TBL] [Abstract][Full Text] [Related]
8. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
9. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines.
Park JW; Yeh MW; Wong MG; Lobo M; Hyun WC; Duh QY; Clark OH
J Clin Endocrinol Metab; 2003 Jul; 88(7):3346-53. PubMed ID: 12843186
[TBL] [Abstract][Full Text] [Related]
10. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
Basso AD; Solit DB; Munster PN; Rosen N
Oncogene; 2002 Feb; 21(8):1159-66. PubMed ID: 11850835
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
12. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
14. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Bonvini P; An WG; Rosolen A; Nguyen P; Trepel J; Garcia de Herreros A; Dunach M; Neckers LM
Cancer Res; 2001 Feb; 61(4):1671-7. PubMed ID: 11245482
[TBL] [Abstract][Full Text] [Related]
15. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
16. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
Nimmanapalli R; O'Bryan E; Bhalla K
Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
[TBL] [Abstract][Full Text] [Related]
18. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation.
Tikhomirov O; Carpenter G
Cancer Res; 2003 Jan; 63(1):39-43. PubMed ID: 12517775
[TBL] [Abstract][Full Text] [Related]
19. Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells.
Nishiyama N; Nori A; Malugin A; Kasuya Y; Kopecková P; Kopecek J
Cancer Res; 2003 Nov; 63(22):7876-82. PubMed ID: 14633716
[TBL] [Abstract][Full Text] [Related]
20. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.
An WG; Schnur RC; Neckers L; Blagosklonny MV
Cancer Chemother Pharmacol; 1997; 40(1):60-4. PubMed ID: 9137531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
